iifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Glemark Pharma recalls 6,528 bottles of blood pressure medicine in US

15 Apr 2024 , 11:29 AM

Glenmark Pharmaceuticals is recalling 6,528 bottles of a high blood pressure drug from the US market owing to failed disintegration criteria, according to the US health authorities.

The US branch of the Mumbai-based drug company is recalling the affected lot of Diltiazem Hydrochloride extended-release capsules, according to the US Food and Drug Administration's most recent Enforcement Report.

The batch in question, manufactured in India, is being recalled by Glenmark Pharmaceuticals Inc., headquartered in New Jersey, due to "failed dissolution specifications," as stated by the USFDA.

The USFDA noted that an Out of Specification (OOS) result occurred during a dissolution test conducted at the 12th month time point in a long-term stability study. Consequently, Glenmark Pharmaceuticals initiated a Class II recall of the medication throughout the United States on March 26 of this year.

According to the USFDA, a Class II recall is undertaken when the use or exposure to a violative product may result in transitory or medically recoverable adverse health effects, or when the likelihood of substantial adverse health consequences is low.

India is the world's largest provider of generic medications, accounting for around 20% of worldwide supply. The country produces 60,000 distinct generic products over 60 therapeutic categories.

The country's products are sent to over 200 countries worldwide, with the primary destinations being Japan, Australia, West Europe, and the United States. India has the most USFDA-compliant enterprises with factories outside of the US.

At around 11.25 AM, Glenmark Pharma was trading 1.13% lower at ₹1,039.90 per piece, against the previous close of ₹1,051.80 on NSE. The counter touched an intraday high and low of ₹1,060, and ₹1,031 respectively.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Glenmark
  • Glenmark Pharma Drug
  • Glenmark Pharma News
  • Glenmark Pharma share price
  • Glenmark Pharma Updates
  • Glenmark Pharma USFDA
sidebar mobile


Read More
Knowledge Centerplus

Logo IIFL Customer Care Number
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

Knowledge Centerplus

Follow us on


2024, IIFL Securities Ltd. All Rights Reserved

  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.